Search

Your search keyword '"Perusini, Maria Agustina"' showing total 28 results

Search Constraints

Start Over You searched for: Author "Perusini, Maria Agustina" Remove constraint Author: "Perusini, Maria Agustina"
28 results on '"Perusini, Maria Agustina"'

Search Results

1. Asparaginase completion among adults including older patients with acute lymphoblastic leukemia treated with a modified DFCI protocol

2. Mutations in myeloid transcription factors and activated signaling genes predict chronic myeloid leukemia outcomes

Catalog

Books, media, physical & digital resources

3. Outcomes and adverse events in older acute lymphoblastic Leukemia patients treated with a pediatric-inspired protocol with Pegylated or native Asparaginase.

4. Prediction of sustained remission after tyrosine kinase inhibitor discontinuation with BCR::ABL1 digital PCR in chronic myeloid leukemia patients.

6. Final report of TKI discontinuation trial with dasatinib for the second attempt of treatment‐free remission after failing the first attempt with imatinib: Treatment‐free Remission Accomplished by Dasatinib (TRAD) study

7. Somatic Mutations Are Frequently Detected in CML Patients before Treatment-Free Remission (TFR) Attempt with Tyrosine Kinase Inhibitor (TKI) Discontinuation but with Uncertain Predictive Value for Tfr Failure

8. Acute Lymphoblastic Leukemia in Patients 60 Years and Older Treated with Pediatric-Inspired Protocols, 20 Years of Follow-up

9. The Prognostic Impact of HMGCLL1 Gene Variant on Treatment Outcomes in Chronic Myeloid Leukemia (CML) Patients: Adverse Impact on the Response, Failure, and Progression with Imatinib Which Can be Abrogated By the Use of 2nd Generation Tyrosine Kinase Inhibitor (TKI) Upfront Therapy

10. Real-World Outcomes and Adverse Events of Elderly Patients with Ph-Negative Acute Lymphoblastic Leukemia Treated with a Pediatric-Inspired Protocol

11. Risk Factor Analysis for Second Treatment-Free Remission Failure from the Canadian TKI Discontinuation (TRAD) Trial in CML Patients: Treatment-Free Remission Accomplished By Dasatinib

12. Outcome of ALL in Adult Patient with Down Syndrome, Single Center Experience

17. An inflammatory state defines a high-risk T-lineage acute lymphoblastic leukemia subgroup

19. Final Report: Somatic Mutations and HMGCLL1 Haplotype Are Not Associated with Molecular Relapse-Free Survival in Patients with Chronic Myeloid Leukemia Who Attempt Treatment-Free Remission

20. New Pattern of Emerging Somatic Mutations in Optimal Responders Following Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia Patients Evidenced from Mutational Kinetic Analysis Based on Pairwise Comparison

22. Propensity Score Matching Comparing Asciminib Versus Ponatinib in Chronic Myeloid Leukemia Patients Who Failed Prior Tyrosine Kinase Inhibitor Therapy

23. Severe thrombocytopenia as a predictor of survival and response to hypomethylating agents in myelodysplastic syndromes: A Latin‐American cohort of 212 patients

24. Allogeneic Haematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia

27. Propensity Score Matching Comparing Asciminib VersusPonatinib in Chronic Myeloid Leukemia Patients Who Failed Prior Tyrosine Kinase Inhibitor Therapy

28. The Prognostic Impact of HMGCLL1Gene Variant on Treatment Outcomes in Chronic Myeloid Leukemia (CML) Patients: Adverse Impact on the Response, Failure, and Progression with Imatinib Which Can be Abrogated By the Use of 2ndGeneration Tyrosine Kinase Inhibitor (TKI) Upfront Therapy